Abstract
(Lancet. 2022;400:542–543) For more than 50 years, antenatal betamethasone has been used as a treatment to reduce neonatal respiratory complications. Evaluating a more recent study examining the risk-to-benefit ratio of the treatment regimen, this article aimed to understand if the dosage of steroids should be reduced in order to minimize risk to the fetus from being exposed to corticosteroids in utero. Some recent studies have indicated correlation between treatment with betamethasone and some physical, mental, or developmental disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
